Tatjana Bundalo

P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC: Topic: EGFR Biomarkers

O. Burghuber, R. Pirker, M. Filipits, 2017 .

Cell‐Free Plasma DNA‐Guided Treatment With Osimertinib in Patients With Advanced EGFR‐Mutated NSCLC

Peter Schenk, Helmut Prosch, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

A. Valipour, G. Absenger, H. Prosch, 2020, Pharmaceuticals.

Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study

B. Ghanim, A. Terbuch, D. Bianconi, 2024, Cancers.